Testosterone
The principal androgen, a C19 steroid; its half-life depends on the ester. Reference entry for the calculators, not tracked for price.
Reference compound, not sold here. Profile for research context only.
Overview
Testosterone is the principal human androgen — a C19 steroid (C19H28O2, 288.4 g/mol), not a peptide — made by testicular Leydig cells under LH drive. Isolated and synthesised in 1935, it has been an FDA-approved prescription drug for decades in intramuscular, subcutaneous, transdermal, oral, nasal and implant forms, all labeled for replacement in men with primary or hypogonadotropic hypogonadism and none for "age-related" low testosterone. It is a Schedule III controlled substance in the US and a WADA S1 prohibited substance. Injectable products are esters in oil, supplied ready to inject — there is nothing to reconstitute. This profile reports label and trial findings; it is not dosing or treatment advice.
Esters compared#
| Ester | Typical half-life | Route | Formulation | Profile |
|---|---|---|---|---|
| Testosterone cypionate | ~8 days (Depo-Testosterone label; no range stated) | IM | 100 or 200 mg/mL in cottonseed oil (Depo-Testosterone, Azmiro) | testosterone-cypionate |
| Testosterone enanthate | ~4.5 days IM (textbook, castor oil); 5.5–10.9 days SC at 200–50 mg (NCT02233751); no US label figure | IM; SC | 200 mg/mL in sesame oil (generic IM); 50/75/100 mg per 0.5 mL SC autoinjector (Xyosted) | testosterone-enanthate |
| Testosterone propionate | ~0.8 days (textbook only; no label or primary PK half-life) | IM | 30 mg/mL component of Sustanon 250 in arachis oil; no current US human product | testosterone-propionate |
| Testosterone undecanoate (injectable) | 33.9 days in castor oil (Behre 1999); 18.3–23.7 days in tea-seed oil (Zhang 1998); Aveed label states none | IM | 750 mg/3 mL in castor oil (Aveed); 1000 mg/4 mL (Nebido); oral capsules are a separate regime | testosterone-undecanoate |
| Free testosterone (reference) | ~27 min slow phase (range 14–32 min across fractions) | IV | Unesterified hormone, Veldhuis 2010 | — |
All injectable figures are apparent, absorption-limited half-lives — serum testosterone falls at the rate the oil depot releases ester, not the minutes it takes to clear the hormone itself — so they describe a formulation, not the molecule.
How it works
Testosterone and its active metabolite dihydrotestosterone are agonists of the androgen receptor, and per the Depo-Testosterone label much of testosterone's activity "appears to depend on reduction to dihydrotestosterone." In plasma it is about 98% bound to sex-hormone-binding globulin. During exogenous administration, endogenous testosterone release is inhibited through feedback inhibition of pituitary LH — which is why testosterone therapy suppresses intratesticular testosterone and spermatogenesis. Pharmacokinetics are dominated by the ester: unesterified testosterone has a slow-phase half-life of roughly 27 minutes after intravenous pulses (14–32 min across free, albumin- and SHBG-bound fractions), so clinical products attach a fatty-acid ester and dissolve it in oil to slow release from the depot — about 8 days for cypionate per its label, ~21–34 days for undecanoate depending on the oil. Plasma half-life therefore says little about how long a dose acts; the depot does.
Evidence
Human evidence is extensive. Replacement trials summarised by Saad et al. (2011) show libido responding in ~3 weeks, mood and lipids in 3–6 weeks, body composition at 12–16 weeks, erythropoiesis at ~3 months (peaking at 9–12), and bone density from ~6 months onward for at least 3 years. The TRAVERSE trial (NEJM 2023; 5,246 hypogonadal men at high cardiovascular risk, mean follow-up 33 months) found transdermal testosterone noninferior to placebo for cardiovascular death, MI or stroke (HR 0.96, 95% CI 0.78–1.17) — settling a long-running safety question — but recorded more atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone arm. Evidence for benefit in men with normal testosterone, or for performance, is not what the labels describe and is outside the approved use.
Anecdotal reports community-reported
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Mood, energy and drivecommonly reported
Users on replacement doses describe more drive, better mood and energy, and gym progress arriving over months rather than days; a common verdict is that it took one to two months to feel better and four to five to see body changes. Several credit diet changes, less alcohol or a GLP-1 taken alongside as much as the testosterone itself, and sleep is often said to be unchanged.
- Libido and sexual functioncommonly reported, with a sizeable negative minority
Cycle-dose users commonly report libido 'like a teenager' and some say it is the main reason they stay on. A sizeable minority report the opposite: low libido and lost morning erections months in, which they attribute to estradiol too low or too high, once-weekly dosing or low SHBG, and several describe fixing it only by changing dose or injection frequency.
- Side effects: estrogen, blood pressure, acne, haircommonly reported
Users describe water retention, higher blood pressure, acne and raised estradiol as the predictable sides, usually managed with lower doses or an aromatase inhibitor; some report hematocrit rising enough to need regular blood donation. Hair shedding is widely reported in those predisposed, and several say it reversed when they dropped back to a replacement dose.
- Anxiety, panic and feeling wireda sizeable minority
Some users describe new panic attacks, irritability and feeling wired after starting, in one case with a patch of hair loss, and say lowering the dose helped but left them more on edge. Others report the reverse, that anxiety they had medicated for eased once levels came up, and a common reply is that a pre-existing anxiety or histamine problem, not the hormone, is the driver.
- The 'rollercoaster' start and expectationscommonly reported
Users warn that the first six to eight weeks are a hormonal rollercoaster as natural production shuts down and the ester builds up, and that nothing is felt from a single injection. Large once-weekly starting doses are widely criticised as a recipe for high estradiol, some who started at 100 mg still 'felt it hard', and a minority a year in remain unconvinced the benefits outweigh the costs.
- Injection frequency and stabilitycommonly reported
Users report very different peak and trough levels on the same 200 mg/week, and many say moving from twice weekly to every other day or daily flattened swings, improved estradiol control and in some cases lowered hematocrit. Others feel fine on one or two shots a week and say some people do worse on frequent injections of long esters; injection site and body fat are often blamed for odd results.
Safety
Labeled adverse reactions include erythrocytosis (the reason for mandatory hemoglobin and hematocrit monitoring), acne and androgenic skin and hair effects, gynecomastia, fluid retention and blood-pressure increases, suppressed spermatogenesis and testicular atrophy, mood changes, venous thromboembolism, and injection-site reactions. Two products carry boxed warnings: Aveed for pulmonary oil microembolism and anaphylaxis (30-minute observation, REMS), and AndroGel for virilisation of children secondarily exposed to the gel. Labels contraindicate testosterone in known or suspected prostate or male breast cancer, pregnancy, and serious cardiac, hepatic or renal disease. Every label's abuse-and-dependence section documents cardiac arrest, heart failure, stroke, liver toxicity and serious psychiatric effects in people who abuse anabolic steroids, and withdrawal after supraphysiologic use. The safety score of 3 reflects a well-mapped but materially risky prescription hormone with real abuse potential; it would be lower for unlabeled or underground products. Prescription-only; nothing here is guidance to use it.
Reported side effects
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Erythrocytosis / polycythemia (raised hemoglobin and hematocrit) — periodic monitoring required per labels
- Acne, seborrhea, hirsutism, male-pattern hair loss
- Gynecomastia, prolonged or frequent erections
- Fluid and electrolyte retention, edema, blood-pressure increases
- Suppression of spermatogenesis and testicular atrophy
- Mood changes — anxiety, depression, libido changes; serious psychiatric effects with abuse
- Venous thromboembolism; in TRAVERSE, more atrial fibrillation, acute kidney injury and pulmonary embolism than placebo
- Injection-site inflammation and pain; pulmonary oil microembolism and anaphylaxis with undecanoate (Aveed boxed warning)
- Secondary exposure of children and partners to transdermal gel (boxed warning)
If severe or unexpected symptoms occur, contact a qualified medical professional. Peptides·Index does not provide medical advice.
Cautions discuss with a clinician
- Known or suspected carcinoma of the prostate, or breast carcinoma in men — androgen-dependent tumours (Depo-Testosterone label)
- Women who are pregnant — virilisation of the female fetus (label); testosterone products other than enanthate for metastatic breast cancer are not indicated in women
- Serious cardiac, hepatic or renal disease — fluid retention and edema risk (Depo-Testosterone label)
- Known hypersensitivity to the drug or vehicle (sesame, cottonseed or castor oil; benzyl alcohol or benzyl benzoate)
- Uncontrolled hypertension — labels for Xyosted and Jatenzo advise against use; blood-pressure increases are a labeled warning across products
- Oral anticoagulants (warfarin)Androgens increase sensitivity, so the anticoagulant dose may need reduction to hold the target INR (label)
- Insulin and other antidiabetic drugsAndrogens may lower blood glucose and reduce insulin requirements in diabetic patients (label)
- OxyphenbutazoneSerum oxyphenbutazone levels may rise with concurrent androgens (label)
- Thyroid function testsAndrogens lower thyroxine-binding globulin, reducing total T4 while free hormone stays normal — a lab artefact, not thyroid disease (label)
Timeline commonly reported
- Weeks 3–6
In the Saad 2011 review of treatment trials, libido changes appear at ~3 weeks and plateau by ~6; mood and quality-of-life changes begin at 3–6 weeks; lipid changes start at ~4 weeks. Insulin sensitivity shifts within days.
- Months 3–6
Erythropoiesis (rising hematocrit) becomes measurable at ~3 months — the reason labels require periodic hemoglobin/hematocrit checks. Fat mass, lean mass and strength changes emerge at 12–16 weeks; erectile effects take up to 6 months.
- Months 6–12 and beyond
Body-composition changes stabilise at 6–12 months; erythropoiesis peaks at 9–12 months; PSA and prostate volume plateau around 12 months; bone-density gains start at ~6 months and continue for at least 3 years. Observed trial timelines, not a promise.
FAQ
Is testosterone a peptide?
No. It is a C19 steroid — four fused carbon rings, formula C19H28O2, 288.4 g/mol — with no amino acids at all. It is on this site because the same audience asks about it alongside hCG, kisspeptin and GH secretagogues, and because our half-life tool covers it.
Is testosterone reconstituted like a peptide?
No. Injectable testosterone is an ester dissolved in oil — cottonseed oil with benzyl benzoate for Depo-Testosterone, sesame oil for enanthate, castor oil with benzyl benzoate for Aveed — supplied ready to inject. There is no lyophilised powder and no bacteriostatic water step, so the reconstitution calculator does not apply.
What is the half-life of testosterone?
It depends on the ester, not the hormone. Free testosterone clears in minutes (slow-phase ~27 min after IV pulses; labels cite 10–100 min). The ester depot sets the real duration: cypionate ~8 days per its label; undecanoate ~34 days in castor oil and ~21 days in tea-seed oil in Behre's phase-I study (18–24 days in Zhang 1998); enanthate's US label gives no figure but doses it every 2–4 weeks, and primate data put it at ~4–5 days. We found no verified human half-life for propionate and do not guess one.
Is testosterone FDA-approved, and for what?
Yes, in many forms — IM cypionate and enanthate, SC enanthate (Xyosted), IM undecanoate (Aveed), oral undecanoate (Jatenzo), transdermal gel (AndroGel), nasal gel (Natesto) and subcutaneous pellets (Testopel) — for replacement in men with primary or hypogonadotropic hypogonadism. Every label states that safety and efficacy for 'age-related hypogonadism' have not been established.
Is testosterone a controlled substance?
In the US, yes: Schedule III under the Controlled Substances Act, and every label carries an abuse-and-dependence section describing cardiac arrest, heart failure, stroke, liver toxicity and psychiatric effects in people who abuse anabolic steroids. It is dispensed only on prescription.
Is testosterone banned in sport?
Yes. It is named in WADA class S1.1 — anabolic androgenic steroids, prohibited at all times when administered exogenously — and the 2026 list spells out that its esters are prohibited too.
Does testosterone therapy raise heart risk?
The large TRAVERSE trial (5,246 men with hypogonadism and high cardiovascular risk, NEJM 2023) found transdermal testosterone noninferior to placebo for major cardiac events (HR 0.96), but with more atrial fibrillation, acute kidney injury and pulmonary embolism. Labels still warn about venous thromboembolism and blood-pressure increases.
Why is hCG used with testosterone?
Exogenous testosterone suppresses the pituitary's LH signal, so the testes stop making their own testosterone and sperm. hCG mimics LH at the testicular receptor and is used off-label to preserve intratesticular testosterone and fertility — see the hCG profile. This describes practice reported in the andrology literature, not advice.
Sources
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.